Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 38 of the 41 references it cites were found in a registry or an index, and 1 are not checked yet.

Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis

Open access

Abstract

OBJECTIVE: In retrospective studies, liver stiffness (LS) by vibration-controlled transient elastography (VCTE) is associated with the risk of liver decompensation in patients with non-alcoholic steatohepatitis (NASH), but prospective data in biopsy-confirmed cohorts with advanced fibrosis are limited. We aimed to establish thresholds for LS by VCTE that predict progression to cirrhosis among patients with bridging fibrosis and hepatic decompensation among patients with cirrhosis due to NASH. DESIGN: We used data from four randomised placebo-controlled trials of selonsertib and simtuzumab in participants with advanced fibrosis (F3-F4). The trials were discontinued due to lack of efficacy. Liver fibrosis was staged centrally at baseline and week 48 (selonsertib study) or week 96 (simtuzumab study). Associations between LS by VCTE with disease progression were determined using Cox proportional hazards regression analysis. RESULTS: Progression to cirrhosis occurred in 16% (103/664) of participants with bridging fibrosis and adjudicated liver-related events occurred in 4% (27/734) of participants with baseline cirrhosis. The optimal baseline LS thresholds were ≥16.6 kPa for predicting progression to cirrhosis, and ≥30.7 kPa for predicting liver-related events. Baseline LS ≥16.6 kPa (adjusted HR 3.99; 95% CI 2.66 to 5.98, p<0.0001) and a ≥5 kPa (and ≥20%) increase (adjusted HR 1.98; 95% CI 1.20 to 3.26, p=0.008) were independent predictors of progression to cirrhosis in participants with bridging fibrosis, while baseline LS ≥30.7 kPa (adjusted HR 10.13, 95% CI 4.38 to 23.41, p<0.0001) predicted liver-related events in participants with cirrhosis. CONCLUSION: The LS thresholds identified in this study may be useful for risk stratification of NASH patients with advanced fibrosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2022-327777

Cites

38 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Research works printed but not linked: 2

  1. Newsome, 2021, Independent validation of Agile 4: novel FibroScan based score for the diagnosis of cirrhosis in patients with non-alcoholic fatty liver disease, J Hepatol, 75, S205
  2. Hsieh, 2015, Correlation between noninvasive markers of fibrosis and hepatic venous pressure gradient in patients with compensated cirrhosis due to nonalcoholic steatohepatitis, Hepatology, 62, 33A

Cited by

See all 114

Metadata

Authors
Loomba, R., Huang, D. Q., Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Ding, D., Ma, L., Jia, C., Billin, A., Huss, R. S., Chung, C., Goodman, Z., Wong, V. W.-S., Okanoue, T., Romero-Gómez, M., Abdelmalek, M. F., Muir, A., Afdhal, N., Bosch, J., Harrison, S., Younossi, Z. M., & Myers, R. P.
Affiliations
  • University of California San Diego (US)
  • National University of Singapore (SG)
  • Virginia Commonwealth University (US)
  • Newcastle University (GB)
  • Medical University of Vienna (AT)
  • The University of Texas at San Antonio Health Science Center (US)
  • Gilead Sciences (United States) (US)
  • Inova Health System (US)
  • Chinese University of Hong Kong (HK)
  • Saiseikai Suita Hospital (JP)
  • Unit for The Clinical Management of Digestive Diseases and CIBERehd, Hospital Universitario de Valme, Sevilla, Spain
  • Duke University (US)
  • Duke Medical Center (US)
  • Harvard University (US)
  • University Hospital of Bern (CH)
  • University of Oxford (GB)
  • Inova Fairfax Hospital (US)
Corresponding author
Loomba, Rohit
Venue
Gut
Publisher
BMJ
Published
2022-09-09
Volume
72
Issue
3
Pages
581-589
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W4295074172
Cited by
110
References
41
Citations by year
2026: 25 · 2025: 29 · 2024: 34 · 2023: 22
FWCI
15.34
Type
journal article
Language
en
Open access
Locations
  • Gut (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • Bern Open Repository and Information System (University of Bern) (submittedVersion)
  • Newcastle University ePrints (Newcastle Univesity)
Funders
  • Gilead Sciences, Inc (NCT03053050; NCT03053063; NCT01672866; NCT01672879)
  • National Center for Advancing Translational Sciences (5UL1TR001442)
  • NIEHS (5P42ES010337)
  • DOD PRCRP (W81XWH-18-2-0026)
  • NIAAA (U01AA029019)
  • National Heart, Lung, and Blood Institute (P01HL147835)
  • National Institute of Diabetes and Digestive and Kidney Diseases (U01DK130190, U01DK061734, R01DK106419, P30DK120515)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
Keywords
liver stiffness, vibration-controlled transient elastography, bridging fibrosis, NASH cirrhosis, disease progression, hepatic decompensation, liver-related events, risk stratification, advanced liver fibrosis, selonsertib
MeSH terms
Benzamides, Humans, Imidazoles, Liver, Liver Cirrhosis, Prospective Studies, Pyridines, Retrospective Studies, Disease Progression, Elasticity Imaging Techniques, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. https://app.cochat.ai/papers/10.1136/gutjnl-2022-327777
The paper
Loomba, R., Huang, D. Q., Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Ding, D., Ma, L., Jia, C., Billin, A., Huss, R. S., Chung, C., Goodman, Z., Wong, V. W.-S., Okanoue, T., Romero-Gómez, M., Abdelmalek, M. F., Muir, A., Afdhal, N., . . . Myers, R. P. (2023). Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. Gut. https://doi.org/10.1136/gutjnl-2022-327777

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.